Table 1.
Reports of patients treated with decitabine for MS.
| Reference | Number of Patients | MS Localization | Number of Cycles | Response | OS (Months) |
|---|---|---|---|---|---|
| Singh SN et al., 2012 [11] | 1 | Lymph node/relapse post HSCT | 13 | CR | 26 |
| Modi G et al., 2015 [12] | 1 | Vagina | 4/ongoing | PR | 4, alive |
| Gornicec M et al., 2017 [13] | 3 | Ear | 9 | Progression to AML | 14 |
| Skin | 6 | Progression to AML | 8 | ||
| Skin/relapse | 3/ongoing | CR | 3, alive | ||
| Evers D et al., 2018 [14] | 1 | Pericardium/relapse post HSCT | 6 + DLI | PR | 6, alive |
| Castelli A et al., 2018 [15] | 1 | Skin + BM/relapse post HSCT | 8 | PR | 8 |
| Minoia C et al., 2019 | 1 | Bilateral breast | 22/ongoing | CR | 27, alive |
OS, overall survival; HSCT, allogeneic hematopoieicstem cell transplant; CR, complete response; PR, partial response; AML, acute myeloid leukemia; DLI, donor lymphocyte infusions.